Switching expensive drugs with frequently diminishing value

被引：0

作者：

Albrecht, J. ^{[1
,2
]}

Gerdes, S. ^{[3
]}

机构：

[1] JH Stroger Hosp Cook Cty, Div Dermatol, Dept Med, Chicago, IL 60612 USA

[2] Rush Med Coll, Dept Dermatol, Chicago, IL 60612 USA

[3] Univ Med Ctr Schleswig Holstein, Psoriasis Ctr, Dept Dermatol, Campus Kiel, Kiel, Germany

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 02期

关键词：

SEVERE PLAQUE PSORIASIS; OPEN-LABEL; MODERATE; ETANERCEPT; COST;

D O I：

10.1111/bjd.15678

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：338 / 339

页数：3

共 9 条

[1]

Abrouk M, 2017, J DERMATOL TREAT, P1

[2] Cost Effectiveness of Biologic Therapies for Plaque Psoriasis [J].

Ahn, Christine S. ;

Gustafson, Cheryl J. ;

Sandoval, Laura F. ;

Davis, Scott A. ;

Feldman, Steven R. .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2013, 14 (04) :315-326

[3] Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab [J].

Bagel, J. ;

Tyring, S. ;

Rice, K. C. ;

Collier, D. H. ;

Kricorian, G. ;

Chung, J. ;

Iles, J. ;

Stolshek, B. S. ;

Kaliyaperumal, A. ;

Papp, K. A. .

BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) :411-418

[4] Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population [J].

Chastek, Benjamin ;

Fox, Kathleen M. ;

Watson, Crystal ;

Kricorian, Gregory ;

Gandra, Shravanthi R. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (01) :25-33

[5]

Elewski BE, 2017, J DERMATOL TREAT, V7, P1

[6] Treatment of Moderate to Severe Plaque Psoriasis With Biologics: Analysis of the Additional Cost of Temporary Dose Escalation vs Switch to Another Biologic After Failure of Maintenance Therapy [J].

Puig, L. .

ACTAS DERMO-SIFILIOGRAFICAS, 2014, 105 (04) :401-412

[7]

Sagonowsky E., 2017, AMGEN HIKES PRICES S

[8]

Vender R, 2011, J DRUGS DERMATOL, V10, P396

[9] An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].

Warren, Richard B. ;

Mrowietz, Ulrich ;

von Kiedrowski, Ralph ;

Niesmann, Johannes ;

Wilsmann-Theis, Dagmar ;

Ghoreschi, Kamran ;

Zschocke, Ina ;

Falk, Thomas M. ;

Bloedorn-Schlicht, Norbert ;

Reich, Kristian .

LANCET, 2017, 389 (10068) :528-537

← 1 →